221 related articles for article (PubMed ID: 31813809)
1. Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course.
DiNatale RG; Gorelick AN; Makarov V; Blum KA; Silagy AW; Freeman B; Chowell D; Marcon J; Mano R; Sanchez A; Attalla K; Weng S; Voss M; Motzer RJ; Russo P; Coleman JA; Reuter VE; Chen YB; Chan TA; Reznik E; Tickoo SK; Hakimi AA
Eur Urol Focus; 2021 Mar; 7(2):381-389. PubMed ID: 31813809
[TBL] [Abstract][Full Text] [Related]
2. TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype.
Hakimi AA; Tickoo SK; Jacobsen A; Sarungbam J; Sfakianos JP; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Chen YB; Sankin A; Mano R; Coleman JA; Russo P; Ogawa S; Sander C; Hsieh JJ; Reuter VE
Mod Pathol; 2015 Jun; 28(6):845-853. PubMed ID: 25676555
[TBL] [Abstract][Full Text] [Related]
3. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
[TBL] [Abstract][Full Text] [Related]
4. Clear cell renal cell carcinoma with wild-type von Hippel-Lindau gene: a non-existent or new tumour entity?
Batavia AA; Schraml P; Moch H
Histopathology; 2019 Jan; 74(1):60-67. PubMed ID: 30565303
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression.
Marcon J; DiNatale RG; Sanchez A; Kotecha RR; Gupta S; Kuo F; Makarov V; Sandhu A; Mano R; Silagy AW; Blum KA; Nassau DE; Benfante NE; Ortiz MV; Carlo MI; Chan TA; Motzer RJ; Voss MH; Coleman J; Russo P; Reuter V; Hakimi AA; Reznik E
Clin Cancer Res; 2020 Jul; 26(14):3629-3640. PubMed ID: 32220885
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma.
Attalla K; DiNatale RG; Rappold PM; Fong CJ; Sanchez-Vega F; Silagy AW; Weng S; Coleman J; Lee CH; Carlo MI; Durack JC; Solomon SB; Reuter VE; Russo P; Chan TA; Motzer RJ; Schultz ND; Reznik E; Voss MH; Hakimi AA
Clin Cancer Res; 2021 Oct; 27(20):5595-5606. PubMed ID: 34261695
[TBL] [Abstract][Full Text] [Related]
7. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.
Becerra MF; Reznik E; Redzematovic A; Tennenbaum DM; Kashan M; Ghanaat M; Casuscelli J; Manley B; Jonsson P; DiNatale RG; Blum KA; Durack JC; Solomon SB; Arcila ME; Bourque C; Socci N; Carlo MI; Lee CH; Voss MH; Feldman DR; Motzer RJ; Coleman JA; Russo P; Cheng EH; Hakimi AA; Hsieh JJ
Eur Urol Focus; 2018 Dec; 4(6):986-994. PubMed ID: 29066084
[TBL] [Abstract][Full Text] [Related]
8. Assessing Genomic Copy Number Alterations as Best Practice for Renal Cell Neoplasia: An Evidence-Based Review from the Cancer Genomics Consortium Workgroup.
Liu YJ; Houldsworth J; Emmadi R; Dyer L; Wolff DJ
Cancer Genet; 2020 Jun; 244():40-54. PubMed ID: 32434132
[TBL] [Abstract][Full Text] [Related]
9. Analysis of clinicopathological and molecular features of ELOC(TCEB1)-mutant renal cell carcinoma.
Wang Y; Zhao P; Wang L; Wang J; Ji X; Li Y; Shi H; Li Y; Zhang W; Jiang Y
Pathol Res Pract; 2022 Jul; 235():153960. PubMed ID: 35653922
[TBL] [Abstract][Full Text] [Related]
10. Renal cell tumors with clear cell histology and intact VHL and chromosome 3p: a histological review of tumors from the Cancer Genome Atlas database.
Favazza L; Chitale DA; Barod R; Rogers CG; Kalyana-Sundaram S; Palanisamy N; Gupta NS; Williamson SR
Mod Pathol; 2017 Nov; 30(11):1603-1612. PubMed ID: 28731045
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
[TBL] [Abstract][Full Text] [Related]
12. The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management.
Weng S; DiNatale RG; Silagy A; Mano R; Attalla K; Kashani M; Weiss K; Benfante NE; Winer AG; Coleman JA; Reuter VE; Russo P; Reznik E; Tickoo SK; Hakimi AA
Eur Urol; 2021 Apr; 79(4):468-477. PubMed ID: 33046271
[TBL] [Abstract][Full Text] [Related]
13. Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients.
Fernandes FG; Silveira HCS; Júnior JNA; da Silveira RA; Zucca LE; Cárcano FM; Sanches AON; Neder L; Scapulatempo-Neto C; Serrano SV; Jonasch E; Reis RM; Evangelista AF
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668731
[TBL] [Abstract][Full Text] [Related]
14. Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture.
Michalova K; Tretiakova M; Pivovarcikova K; Alaghehbandan R; Perez Montiel D; Ulamec M; Osunkoya A; Trpkov K; Yuan G; Grossmann P; Sperga M; Ferak I; Rogala J; Mareckova J; Pitra T; Kolar J; Michal M; Hes O
Ann Diagn Pathol; 2020 Feb; 44():151448. PubMed ID: 31918172
[TBL] [Abstract][Full Text] [Related]
15. Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
Togo Y; Yoshikawa Y; Suzuki T; Nakano Y; Kanematsu A; Zozumi M; Nojima M; Hirota S; Yamamoto S; Hashimoto-Tamaoki T
Int J Oncol; 2016 Apr; 48(4):1571-80. PubMed ID: 26891804
[TBL] [Abstract][Full Text] [Related]
16. A genomic mutation spectrum of collecting duct carcinoma in the Chinese population.
Zhang H; Lu X; Huang G; Hua M; Zhang W; Wang T; Huang L; Wang Z; Chen Q; Li J; Yang Q; Yang G
BMC Med Genomics; 2022 Jan; 15(1):1. PubMed ID: 34980126
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling.
Pal SK; Choueiri TK; Wang K; Khaira D; Karam JA; Van Allen E; Palma NA; Stein MN; Johnson A; Squillace R; Elvin JA; Chmielecki J; Yelensky R; Yakirevich E; Lipson D; Lin DI; Miller VA; Stephens PJ; Ali SM; Ross JS
Eur Urol; 2016 Sep; 70(3):516-21. PubMed ID: 26149668
[TBL] [Abstract][Full Text] [Related]
18. Sporadic oncocytic tumors with features intermediate between oncocytoma and chromophobe renal cell carcinoma: comprehensive clinicopathological and genomic profiling.
Liu YJ; Ussakli C; Antic T; Liu Y; Wu Y; True L; Tretiakova MS
Hum Pathol; 2020 Oct; 104():18-29. PubMed ID: 32673684
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters.
Kondo K; Yao M; Yoshida M; Kishida T; Shuin T; Miura T; Moriyama M; Kobayashi K; Sakai N; Kaneko S; Kawakami S; Baba M; Nakaigawa N; Nagashima Y; Nakatani Y; Hosaka M
Genes Chromosomes Cancer; 2002 May; 34(1):58-68. PubMed ID: 11921283
[TBL] [Abstract][Full Text] [Related]
20. Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others.
Li H; Argani P; Halper-Stromberg E; Lotan TL; Merino MJ; Reuter VE; Matoso A
Am J Surg Pathol; 2023 Nov; 47(11):1267-1273. PubMed ID: 37661807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
